Relevant bibliographies by topics / Potential biomaker

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Potential biomaker'

Author: Grafiati
Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Potential biomaker.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Potential biomaker"

1

Pavoni-Ferreira, P. C., A. S. Petrilli, M. T. Alves, R. Jesus-Garcia Filho, and S. R. Toledo. "Angiogenic biomaker study in osteosarcoma." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e21507-e21507. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e21507.

Full text
Abstract:
e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients. Methods: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR. Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity. Results: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed. SDF1 gene has the lowest expression at all. In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001). VEGFR1 expression was higher than VEGFR2 expression (P=0.001). PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005). VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively. In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression. Conclusions: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis. TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001). Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
2

Hashimoto, T., T. Hata, Y. Mori, J. Suzuki, Y. Kamata, K. Yoshimura, M. Kunou, et al. "P17-3 Evaluating event-related potential P50 suppression for diagnostic biomaker for psychiatric disorders." Clinical Neurophysiology 121 (October 2010): S203—S204. http://dx.doi.org/10.1016/s1388-2457(10)60836-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Li, Chen, Hui Geng, Linhua Ji, Xiaojing Ma, Qichao Yin, and Hua Xiong. "ESM-1: A Novel Tumor Biomaker and its Research Advances." Anti-Cancer Agents in Medicinal Chemistry 19, no. 14 (December 16, 2019): 1687–94. http://dx.doi.org/10.2174/1871520619666190705151542.

Full text
Abstract:
Background:Cancer kills nearly 9,000,000 people worldwide, and its mortality was reported up to 28% in the past decade. Few available tumor markers have been known to help early stage diagnosis. In this study, Endocan was taken as a novel tumor marker, which has been found in many cancers related to cancer cell proliferation, neoangiogenesis, etc.Methods:Studies on Endocan and its correlation with cancer were reviewed, and key points of meaningful studies on the structure, pathways and targeted agents of Endocan were drawn.Results:Endocan leads to tumorigenesis and promotes tumor cells proliferation via HGF/SF signal transmission pathway, suppresses tumor cells apoptosis via NF-κB signaling pathway and promotes angiogenesis within tumors via VEGF and HIF pathway. Medicine suppressing the expression of Endocan could prevent tumorigenesis and even improve survival rate of mice with tumor significantly.Conclusion:Endocan is capable of promoting prognosis of cancer patients. Moreover, Endocan is supposed to a potential target of tumor-targeted therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Nafi’u, S. A., K. Suleiman, M. K. Ahmad, and M. Zakariyya. "Effect of Paraquat Herbicide on Oxidative Stress Biomaker Enzyme Activities in C. Gariepinus." Dutse Journal of Pure and Applied Sciences 7, no. 3b (January 6, 2022): 48–59. http://dx.doi.org/10.4314/dujopas.v7i3b.6.

Full text
Abstract:
Toxicity assessment was conducted for 96hr exposure duration using synthetic herbicide (paraquat dichloride 276g/L) on Claris gariepinus with mean weight range of 27.2 - 29.7g and mean length 10.95 -15.5cm. They were exposed to varying herbicide concentrations of 0.0, 3.45, 6.90, 10.35 and 13.5mg/L with 5-levels exposure concentrations in a Completely Randomized Design (CRD). Liver, gills and kidney tissues were analyzed for oxidative stress enzymes activities using Solarbio science assay kit (BC1170, 0170 and 0020). Four days lethal concentration (LC50) value for 96hr was found to be 7.298mg/L. The treated fish displayed erratic swimming with irregular opercular movement, loss of reflex, mucus secretion and increased air gulping with the increasing concentration of the herbicide compared with the control fish. Antioxidant biomarkers activities revealed that Glutathione S-transferase (GST), catalase (CAT) and superoxide dismutase (SOD) activities increased significantly (P<0.05) in the gills, liver and kidney tissues at higher concentrations compared with control. It can be deduced that alterations in the oxidative stress enzyme activities in the exposed fish to paraquat exert toxic effect on the liver, gills and kidney tissues. It is therefore recommended that appropriate authorities should develop strategies on minimizing the indiscriminate use of synthetic herbicides due to their impact on aquatic biota such as fish in order to reduce its potential risk to other non-target organisms. Keywords: Clarias gariepinus, Lethal concentration, Oxidative Stress enzymes, Paraquat, Toxicity assessment
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Tianju, Andrew E. Rinke, Kevin Flaherty, and Sem Hin Phan. "Soluble B7H3 induction in pulmonary fibrosis is associated with disease severity." Journal of Immunology 204, no. 1_Supplement (May 1, 2020): 146.9. http://dx.doi.org/10.4049/jimmunol.204.supp.146.9.

Full text
Abstract:
Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease with limited therapeutic options. Both innate and adaptive immune mechanisms contribute to fibrogenesis. B7 family member B7H3, identified as important regulator of the immune system, has been implicated in cancer, graft-versus host disease, and allergy-related disease. Increased soluble B7H3 (sB7H3) was associated with enhanced lung fibrosis in mice receiving BLM-primed BM. Elevated sB7H3 in bronchoalveolar lavage fluid was associated with acute exacerbation IPF. To investigate whether induced sB7H3 could be used as a biomaker for IPF diagnosis and/or prognosis, plasma sB7H3 from control subjects and IPF patients was measured by ELISA. Its correlation with peripheral blood immune cells, lung function, and drug treatments were evaluated in this study. The results showed that the sB7H3 level was significantly elevated in IPF patients. This induction was associated with increased circulating B7H3+ cells, and significantly correlated with increased granulocytic myeloid-derived suppressive cells (G-MDSCs). This suggests a potential regulatory role of the induced B7H3 in the immune response in IPF. The plasma sB7H3 was negatively correlated with lung function measured as diffusing capacity of the lungs for carbon monoxide (DLCO), indicating the potential utility of plasma sB7H3 as an indicator of disease severity. The slightly elevated sB7H3 in the pirfenidone and/or nintedanib treated IPF patients were not significantly different relative to controls, which was in contrast to the significant elevation noted for the untreated patients. These findings suggest that sB7H3 may be a useful biomarker for clinical assessment of prognosis and response to drug treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

B. Veena, B. Veena. "Bioinformatics Analysis of Mirna Data for Potential Biomarker Discovery." International Journal of Scientific Research 2, no. 8 (June 1, 2012): 45–47. http://dx.doi.org/10.15373/22778179/aug2013/16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

McNamara, Aoife E., and Lorraine Brennan. "Potential of food intake biomarkers in nutrition research." Proceedings of the Nutrition Society 79, no. 4 (July 2, 2020): 487–97. http://dx.doi.org/10.1017/s0029665120007053.

Full text
Abstract:
The influence of dietary habits on health/disease is well-established. Accurate dietary assessment is essential to understand metabolic pathways/processes involved in this relationship. In recent years, biomarker discovery has become a major area of interest for improving dietary assessment. Well-established nutrient intake biomarkers exist; however, there is growing interest in identifying and using biomarkers for more accurate and objective measurements of food intake. Metabolomics has emerged as a key tool used for biomarker discovery, employing techniques such as NMR spectroscopy, or MS. To date, a number of putatively identified biomarkers were discovered for foods including meat, cruciferous vegetables and legumes. However, many of the results are associations only and lack the desired validation including dose–response studies. Food intake biomarkers can be employed to classify individuals into consumers/non-consumers of specific foods, or into dietary patterns. Food intake biomarkers can also play a role in correcting self-reported measurement error, thus improving dietary intake estimates. Quantification of food intake was previously performed for citrus (proline betaine), chicken (guanidoacetate) and grape (tartaric acid) intake. However, this area still requires more investigation and expansion to a range of foods. The present review will assess the current literature of identified specific food intake biomarkers, their validation and the variety of biomarker uses. Addressing the utility of biomarkers and highlighting gaps in this area is important to advance the field in the context of nutrition research.
APA, Harvard, Vancouver, ISO, and other styles
8

K. Mohammed, Lona, and Sarhang S. Gul. "Diagnostic Potential of Salivary Biomarker Profiles in Epidemiological Survey of Periodontitis." Sulaimani dental journal 7, no. 2 (January 12, 2020): 36–44. http://dx.doi.org/10.17656/sdj.10114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Priya, Shalini, Alina Peluso, Mayanka Chandra Shekhar, Ioana Danciu, Jordan Miller, and Heidi A. Hanson. "Abstract 4191: Assessing performance of biomarker extraction from electronic health records: Data augmentation methods for a hierarchical self-attention network (HiSAN)." Cancer Research 83, no. 7_Supplement (April 4, 2023): 4191. http://dx.doi.org/10.1158/1538-7445.am2023-4191.

Full text
Abstract:
Abstract Background: Extraction of HER2 status from electronic health records (EHR) may expedite clinical trials matching and be used for survivorship research. Deep learning (DL) algorithms have potential to extract this data; however, inherent class imbalance leads to reduced model performance. We compare state of the art strategies to handle class imbalance in models trained to extract HER2 status. This comparative analysis may be used as a guideline for HER2 extraction. Methods: 680,117 pathology reports collected from 2017-2021 by the National Cancer Institutes’ Surveillance, Epidemiology, and End-Results (SEER) program were used for this study. Pathology reports are manually labelled by cancer registrars as HER2 -, HER2+, or Unknown (class ratio 65%, 11%, 24% respectively). We compare six data augmentation (DA) methods: balanced frequency weighting, ROS while up-sampling HER2+ by 595%, RUS while down-sampling HER2- by 83%, SMOTE, ADASYN, and SMOTE-Tomek. As a comparison we consider the HiSAN model i.e., a DL architecture currently used by SEER for automatic classification of reports. Result: Applying DA strategies did not improve the performance of the HiSAN model (Table 1). Frequency based class-weighting (Acc=0.78), ROS (Acc=0.81), and RUS (Acc=0.80) perform worse than the baseline model, suggesting simple data augmentation methods do not boost performance for this task. Advanced oversampling with SMOTE (Acc=0.88) and ADASYN (Acc=0.88) perform better than simple approaches, but do not improve the predictive accuracy of the baseline HiSAN. Conclusion: Common DA methods do not improve the performance of the HiSAN biomaker method. While the overall accuracy of the baseline HiSAN model is quite high, other methods for improved accuracy should be explored. Table 1. Method Accuracy (Acc) Sensitivity Specificity Precision HiSAN (Baseline) 0.8898 0.7583 0.8944 0.8507 Frequency class weighting 0.7826 0.8033 0.8932 0.7040 Random Over Sampling (ROS) 0.8057 0.7672 0.8883 0.7130 Random Under Sampling (RUS) 0.8042 0.7883 0.8930 0.6902 Synthetic Minority Oversampling Technique (SMOTE) 0.8796 0.7341 0.8827 0.8340 Adaptive Synthetic Sampling (ADASYN) 0.8764 0.7467 0.8863 0.8142 SMOTE-Tomek 0.8823 0.7620 0.8956 0.8200 Citation Format: Shalini Priya, Alina Peluso, Mayanka Chandra Shekhar, Ioana Danciu, Jordan Miller, Heidi A. Hanson. Assessing performance of biomarker extraction from electronic health records: Data augmentation methods for a hierarchical self-attention network (HiSAN). [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4191.
APA, Harvard, Vancouver, ISO, and other styles
10

Ebadi, Maryam, and Vera C. Mazurak. "Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia." Mediators of Inflammation 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/820934.

Full text
Abstract:
Fat loss is associated with shorter survival and reduced quality of life in cancer patients. Effective intervention for fat loss in cachexia requires identification of the condition using prognostic biomarkers for early detection and prevention of further depletion. No biomarkers of fat mass alterations have been defined for application to the neoplastic state. Several inflammatory cytokines have been implicated in mediating fat loss associated with cachexia; however, plasma levels may not relate to adipose atrophy. Zinc-α2-glycoprotein may be a local catabolic mediator within adipose tissue rather than serving as a plasma biomarker of fat loss. Plasma glycerol and leptin associate with adipose tissue atrophy and mass, respectively; however, no study has evaluated their potential as a prognostic biomarker of cachexia-associated fat loss. This review confirms the need for further studies to identify valid prognostic biomarkers to identify loss of fat based on changes in plasma levels of biomarkers.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Potential biomaker"

1

Frederickx, Nancy. "The SLC22A18 transporter, a potential biomarker for chemotherapeutic treatment." Doctoral thesis, Universite Libre de Bruxelles, 2015. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/217862.

Full text
Abstract:
SUMMARYThe diversity of cancer molecular origins associated with the genetic variability of patients has encouraged the development of chemotherapeutic treatments adapted not only to the target tumor, but also to a specific patient. This personalized strategy is based on cancer biomarkers allowing a better identification and characterization of each tumor where predictive biomarkers provide the distinction between various factors indicative of the response to the treatment. In this context, several studies highlighted the role of the solute carrier transporter family 22 (solute carriers 22 or SLC22) in the uptake of platinum anticancer drugs. This mechanism being not well understood, our work intends to establish the potential role of SLC22 member A18 (SLC22A18) as predictive biomarker in the aim to help to a better targeted chemotherapeutic strategy for each patient. We optimized a system overexpressing SLC22A18 stably or transiently in HeLa cancer cell line. SLC22A18 expression was confirmed by qRT-PCR, western blotting, microscopy and flow cytometry. The cell lines were treated with taxane, anthracyclin, vinca alkaloid and nitrosoureas anticancer drug families. We showed that doxorubicin, camptothecin, chloroquine, tetracycline and carmustin had no effect on the cell viability assays suggesting that they are not substrates of SLC22A18. Interestingly, the cell line was sensitized in the presence of antimitotic drug with a sensitivity factor of 2.7 in the presence of paclitaxel, 1.4 with docetaxel, 1.8 with vinblastin and 2.2 in the presence of vincristine. To confirm these results, we elaborated a SLC22A18 knockdown cell line in HS683 cells using siRNA technology. The downexpression of SLC22A18 was correlated to a tendency to resist to the accumulation of paclitaxel thereby confirming the previous results. Simultaneously, a knockout cell line was established using the transcription activator-like effectors nuclease (TALEN) technology in U373 cell line. Our studies constitute a robust base of knowledge for further investigation on SLC22A18 transporter as a predictive biomarker promoting antimitotic treatment in tumors where this transporter is detected.
Doctorat en Sciences
info:eu-repo/semantics/nonPublished
APA, Harvard, Vancouver, ISO, and other styles
2

Santos, Joana Rita Faneca. "TAU Thr231 phosphorylation as a potential Alzheimer's disease biomarker." Master's thesis, Universidade de Aveiro, 2017. http://hdl.handle.net/10773/22056.

Full text
Abstract:
Mestrado em Biomedicina Molecular
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the presence of extracellular amyloid plaques (senile plaques) and intracellular neurofibrillary tangles formed by hyperphosphorylated TAU protein. TAU protein when hyperphosphorylated loses the ability to bind to microtubules and can be released into peripheral fluids. This process leads to neuronal degradation and neuronal death. Phosphorylation at threonine 231 has been shown to be specific for AD and to precede assembly of paired helical filaments in the human brain. In order to understand more about this residue we analysed SH-SY5Y cells undifferentiated and in differentiated cells induced by retinoic acid (RA). Treatment with RA increased expression of TAU phosphorylated at Thr231 (TAUpThr231) as determined by Western blot analysis. We further explored TAU phosphorylation by immunocytochemistry and noticed that in undifferentiated SH-SY5Y cells, TAUpThr231 was located mainly in the nucleus. In contrast, TAU and TAUpThr231 was redistributed to the neurites and in the soma of SH-SY5Y cells, which were induced to differentiate by retinoic acid (RA). In order to evaluate the potential of TAUpThr231 as a biomarker, we measured TAUpThr231 in CSF by a sandwich enzyme immunoassay and observed that the ratio of TAUpThr231/TAU levels discriminated significantly the AD group for the non-AD group. These findings indicate that TAUpThr231/t-TAU ratio levels may be a valuable marker for the clinical diagnosis of AD, irrespective of age and gender.
A doença de Alzheimer (AD) é uma doença neurodegenerativa progressiva caracterizada pela presença de placas de amilóide extracelulares (placas senis) e tranças neurofibrilhares intracelulares formadas pela proteína TAU hiperfosforilada. A proteína TAU quando hiperfosforilada perde a capacidade de se ligar a microtúbulos e pode ser libertada para fluidos periféricos. Este processo leva à degradação neuronal e à morte neuronal. A fosforilação na treonina 231 tem-se demonstrado ser específica para a AD e preceder a formação de filamentos helicoidais emparelhados no cérebro humano. Para melhor perceber a função deste resíduo e a contribuição para a localização da TAU, analisámos células SH-SY5Y indiferenciadas e células diferenciadas, pela adição de ácido retinoico (RA). O tratamento com RA aumentou a expressão de TAU fosforilada na Thr231 (TAUpThr231) conforme determinado por Western blot. Explorámos ainda a fosforilação da TAU por imunocitoquímica e percebemos que em células SH-SY5Y indiferenciadas, a phosphoTAU231 estava localizada principalmente no núcleo. Em contraste, TAU e phosphoTAU231 foram redistribuídas para as dendrites e citosol das células SH-SY5Y diferenciadas pelo ácido retinoico (RA). Para avaliar o potencial deste resíduo como biomarcador; medimos TAUpThr231 em CSF por meio de um imunoensaio enzimático em sanduíche e observámos que a proporção de níveis de TAUpThr231 / TAU discriminou de forma significativa o grupo AD do grupo não-AD. Essas descobertas podem indicar que os níveis da relação TAUpThr231 / t-TAU podem ser um marcador valioso para o diagnóstico clínico de AD, independentemente da idade e do género.
APA, Harvard, Vancouver, ISO, and other styles
3

Almeida, João Carlos Moutinho de. "DNA methylation as a potential biomarker for Alzheimer disease." Master's thesis, Universidade de Aveiro, 2013. http://hdl.handle.net/10773/13261.

Full text
Abstract:
Mestrado em Biomedicina Molecular
DNA methylation is the major studied epigenetic mechanism and consists in the addiction of a methyl group to 5’ carbon position of the cytosine ring. Methylation of promoter gene regions are directly correlated with gene silencing, which can allow the development of certain diseases since relevant genes may be inhibited due to its promoter methylation; being that the opposite can also occur. This epigenetic mechanism has been linked to cancer and recently it is also being pointed to have an important role in neurological disorders, such as Alzheimer’s Disease (AD). Furthermore, aging is the major risk factor for AD, and also the process underlying many of the epigenetic alterations. As AD etiology and pathological development is not complete understood, alterations in epigenetic mechanisms like DNA methylation may underlie the basis of gene expression alterations. Hence, in this study, possible AD patients and age- and sex-matched controls were used. Genomic DNA was extracted from blood samples and the global methylation levels were determined using an ELISA-type assay, The possible AD patients exhibit lower methylation levels (0,75%±0,29) than age- and sex-matched controls (0,86%±0,29). Gene specific methylation profiles of AD related genes, namely APP and ApoE, was carried out using Combine Bisulfite Restriction Analysis (COBRA), Methylation Sensitive-High Resolution Melting (MS-HRM) and Bisulfite Direct Sequencing. The APP promoter region did not reveal any methylation by COBRA and MS-HRM. For the ApoE promoter region evaluated no differences in the methylation levels could be detected between patients and controls using these two techniques. However, by sequencing analysis of this ApoE promoter region, differences arise in specific CpG sites, indicating a tendency for increased methylation of CpG1, CpG3 and CpG 5 and a decreased methylation of CpG6 in AD patients when compared with age- and sex-matched controls. In this study AD patients exhibited a tendency for lower global methylation levels when compared to control individuals and the ApoE promoter region exhibited a tendency for a pattern of methylation that maybe related to AD pathology.
A metilação de DNA é, de todos os mecanismos epigenéticos, o mais estudado e consiste na adição de um grupo metil ao carbono da posição 5 do anel de uma citosina. A metilação da região promotora de genes está diretamente relacionada com silenciamento genético, podendo conduzir ao desenvolvimento de determinadas patologias, uma vez que genes importantes não são expressos devido a este mecanismo. Este mecanismo epigenético tem vindo a ser estudado a nível do cancro e, recentemente, tem adquirido alguma importância ao nível de doenças neurológicas, como a doença de Alzheimer (DA). O envelhecimento é o maior factor de risco para a DA e ao mesmo tempo está na base de muitas das alterações nos mecanismos epigenéticos. Como a patologia e etiologia da DA ainda não é completamente conhecida, alterações ao nível de mecanismos epigenéticos, como a metilação de DNA, podem ajudar a entender as alterações de expressão de genes nesta doença. Neste estudo, utilizaram-se amostras de pacientes com possível DA e controlos com idades semelhantes. O DNA genómico foi extraído de amostras de sangue e os níveis de metilação global foram avaliados por um ensaio de ELISA. Os pacientes apresentaram uma tendência para uma diminuição da metilação global (0,75%±0,29) relativamente aos controlos (0,86%±0,29). Os perfis de metilação dos genes envolvidos na DA, APP e ApoE, foram obtidos por Combine Bisulfite Restriction Analysis (COBRA), Methylation Sensitive - High Resolution Melting (MS-HRM) e Bisulfite Direct Sequencing (BDS). Para a região promotora do gene ApoE, não foram encontradas diferenças entre pacientes e controlos assim como a região promotora do gene APP não apresentou metilação através do método COBRA e MS-HRM. De igual modo, a região promotora do gene ApoE também não apresentou diferenças usando estas 2 técnicas. No entanto, a BDS evidenciou diferenças em locais CpGs específicos, mostrando que existe uma tendência para o aumento da metilação nos CpGs 1, 3 e 5; e para diminuição da metilação no CpG 6 dos pacientes relativamente aos indivíduos control. Este estudo permitiu verificar uma tendência para de diminuição da metilação global dos pacientes com possível DA relativamente aos controlos e também a existência de um possível padrão de metilação da região promotora do gene ApoE, que pode estar relacionado com a patologia da DA .
APA, Harvard, Vancouver, ISO, and other styles
4

Sharpe, Benjamin Peter. "Prostate cancer stem cells : potential new biomarkers." Thesis, University of Bath, 2016. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.698969.

Full text
Abstract:
Prostate cancer is a leading cause of cancer-related death in men, and while many men diagnosed with the disease will have an indolent clinical course, 20-25% of men will experience disease recurrence which is invariably lethal. There is an urgent need for prognostic biomarkers that will predict disease recurrence and risk-stratify patients upon diagnosis, allowing for personalised therapies. This thesis attempts to identify new prognostic biomarkers for prostate cancer and investigates their patterns of protein expression in human primary prostate tumour tissue. Cancer stem cells are cancer cells thought to be uniquely capable of self-renewal and tumorigenicity, and may have a role in tumour recurrence. Using a literature searching approach, potential biomarkers related to stem cells, cancer stem cells or recurrence in prostate cancer were identified, and ALDH7A1, BMI1, SDC1, MUC1-C, Nestin and ZSCAN4 were chosen for investigation. An in silico approach was also used for biomarker identification, with RS1 and SLC31A1 selected as their mRNA was found to be upregulated in recurrent tumours. The expression patterns of all 7 potential biomarkers were examined by immunohistochemistry on prostate tumour tissue and benign tissue from prostate biopsies and prostatectomies. BMI1, ALDH7A1, MUC1-C and Nestin showed no relationship to recurrence or other clinical features. RS1 protein levels increased in patients with recurrence within 5 years, negatively correlated with AR expression, and a meta-analysis showed that the RS1 gene was amplified in up to 32% of castration-resistant prostate tumours. ZSCAN4 was heterogeneously expressed in a subset of 26% of prostate tumours with unclear characteristics and was not expressed in benign tissue, but was not associated with recurrence. Finally, SDC1 expression was lost in tumour epithelium, but a population of unidentified SDC1-expressing cells were found in the stroma of a third of tumours, and an increased burden of these cells was associated with primary Gleason pattern 5 tumours. These cells do not overlap with common epithelial, mesenchymal or stromal lineages, but may be migratory. In summary, the data presented in this thesis identifies 3 potential new biomarkers for prostate cancer, and provides the basis for future characterisation of their wider roles in the disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Rankin, Naomi. "Immunoglobulin G glycoslation as a potential biomarker for multiple sclerosis." Thesis, University of Strathclyde, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.538908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Thomas, Joanna. "Brown adipose tissue a potential early biomarker of metabolic syndrome /." Diss., [La Jolla] : University of California, San Diego, 2009. http://wwwlib.umi.com/cr/ucsd/fullcit?p3356437.

Full text
Abstract:
Thesis (Ph. D.)--University of California, San Diego, 2009.
Title from first page of PDF file (viewed July 9, 2009). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
7

Thermaenius, Elisabeth. "Prostasome ELISA - a potential marker for prostate cancer diagnosis." Thesis, Uppsala universitet, Institutionen för medicinsk biokemi och mikrobiologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-179493.

Full text
Abstract:
Abstract   The prostate gland, a male organ, situated right under the urine bladder, is involved in male reproduction. It can also be the place for more or less serious diseases such as inflammation, abnormal growth and cancer. Especially prostate cancer is very common in the Western world. Today PSA is the most widely used marker for detection of prostate cancer. Unfortunately, this method is not specific enough. Therefore, there is a need for a better marker for screening of malignant prostate cancer. The marker should be specific both for the organ prostate and for the cancer disease. One promising marker is the prostasome, a small vesicle emanating from epithelial cells in the ejaculatory ducts in the prostate. The aim of this project was to set up an ELISA and test a number of antibodies for their ability to work as suitable capture or detection antibodies. As blocking agent different concentrations of BSA were tested. Biotin-Streptavidin conjugate was used in the detection step. Two surface proteins, PSCA and PSMA were used as capture antigens; they are specific for prostasomes. Clusterin, a prostasomal surface-bound protein, was used as antigen for the secondary antibody in the assay. With this experimental setup the detection limit was 2500ng/mL, which is probably not enough to detect prostasomes in cancer. The development of the ELISA did not reach its final stage, a ready-to-use assay, during this project. We have not yet the knowledge of optimal antibody concentrations and the other test parameters are also at experimental state.
APA, Harvard, Vancouver, ISO, and other styles
8

Hamid, Umi Marshida Abd. "Glycosylation-based approaches for potential breast cancer biomarkers." Thesis, University of Oxford, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.540155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ashtaputre, Ravina M. "Potential Biomarkers for Preterm Delivery in Amniotic Fluid." Wright State University / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=wright1464186519.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Macedo, Bárbara Beatriz Pinto. "Aldehyde dehydrogenases as potential biomarkers in myeloid neoplasias." Master's thesis, Universidade de Aveiro, 2018. http://hdl.handle.net/10773/22674.

Full text
Abstract:
Mestrado em Bioquímica - Métodos Biomoleculares
A superfamília das desidrogenases dos aldeídos (ALDH) é constituída por 19 enzimas cuja principal função é a proteção do organismo contra aldeídos tóxicos. As ALDHs têm sido associadas ao desenvolvimento de múltiplas doenças. As síndromes mielodisplásicas (SMD) são caracterizadas por hematopoiese ineficaz associada a citopenias no sangue periférico e elevada predisposição para transformação leucémica. A leucemia mieloide aguda (LMA) é caracterizada por crescimento anómalo de células mieloides imaturas no sangue e na medula óssea. A fisiopatologia das SMDs e LMAs é um processo complexo de múltiplas etapas que envolve alterações genéticas e epigenéticas numa ampla variedade de genes associados à diferenciação, proliferação, auto-renovação e apoptose celulares. Uma vez que as ALDHs estão envolvidas em alguns destes processos biológicos, a desregulação destas enzimas pode influenciar o desenvolvimento de SMD e LMA. O objetivo deste estudo é avaliar a expressão génica das ALDHs em doentes com SMD e LMA de modo a verificar seu potencial como biomarcadores de diagnóstico e/ou prognóstico destas doenças. Neste contexto, analisou-se a expressão da ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, ALDH1L2, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH7A1, ALDH16A1 e ALDH18A1 por PCR de transcriptase reversa. Os genes diferencialmente expressos (ALDH3A2, ALDH3B1, ALDH4A1 e ALDH18A1) foram quantificados, por PCR em tempo real, em 54 doentes, 34 com SMD e 20 com LMA, e em 34 controlos saudáveis. A análise estatística foi realizada com recurso aos testes de Kolmogorov-Smirnov, Mann-Whitney, Kruskal-Wallis e análise ROC. As diferenças foram consideradas significativas quando p<0.05. Os resultados mostraram que para as ALDH1A3, ALDH1L1, ALDH1L2, ALDH3A1, ALDH3B2 e ALDH5A1 não existem diferenças de expressão entre doentes com SMD, doentes com LMA e controlos. Os doentes com SMD e LMA apresentam níveis de expressão de ALDH3A2 (SMD: mediana 1.9251; distância interquartil 1.28; p=0.000618; LMA: mediana 1.5096; distância interquartil 0.99; p=0.008) e ALDH4A1 (SMD: mediana 0.1841; distância interquartil 0.47; p=0.01134; LMA: mediana 0.1635; distância interquartil 0.78; p=0.124) superiores aos observados nos controlos (ALDH3A2: mediana 0.4624; distância interquartil 1.53; ALDH4A1: mediana 0.0388; distância interquartil 0.12). Por outro lado, os doentes com SMD apresentam níveis de expressão mais elevados de ALDH3B1 (mediana 1.6445; distância interquartil 1.39) do que os doentes com LMA (mediana 0.4541; distância interquartil 0.47; p=0.000314) e controlos (mediana 0.3521; distância interquartil 0.51; p=5.9942E-07). Os diferentes subtipos de SMD apresentam expressão diferencial de ALDH3A2 e ALDH3B1. Além disso, os doentes com SMD e com LMA com alterações mielodisplásicas não expressam ALDH18A1. Seguidamente avaliou-se a expressão das ALDHs nos doentes de SMD estratificados de acordo com o WPSS (WHO classification-based Prognostic Scoring System) e verificou-se que os doentes de muito baixo risco apresentaram maior expressão de ALDH3B1 (mediana 17.6934; distância interquartil 16.32) comparativamente aos de risco intermédio (mediana 1.2352; distância interquartil 2.55; p=0.010) . Por fim, a expressão das isoformas de ALDH não parece influenciar a sobrevivência global de doentes com SMD e LMA ou a evolução de SMD para LMA. Em conclusão, este trabalho sugere que as isoformas de ALDH apresentam expressão diferencial em doentes com SMD e LMA relativamente a indivíduos saudáveis e entre si. A expressão de ALDH3B1 poderá ser um potencial biomarcador de diagnóstico de SMD. Além disso, uma vez que nenhum doente com SMD e LMA com alterações mielodisplásicas apresenta expressão da ALDH18A1, a expressão desta isoforma poderá ser um bom biomarcador de diagnóstico de mielodisplasia. Por fim, a expressão de ALDH3A2 demostrou ser um possível biomarcador de diagnóstico de LMA. No entanto, estudos adicionais com um maior número de amostras são necessários para provar o potencial dessas enzimas como biomarcadores de diagnóstico.
Aldehyde Dehydrogenase (ALDH) superfamily is a group of 19 enzymes critical to the protection against toxic aldehydes, and have been associated with multiple diseases. Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis associated with peripheral blood cytopenias, and a predisposition toward leukemic transformation. Acute myeloid leukemia (AML) are characterized by disordered growth of immature myeloid blood cells in the blood and bone marrow. The pathophysiology of both, MDS and AML, is a complex multistep process that involves genetic and epigenetic abnormalities in a wide variety of genes associated with differentiation, cellular proliferation, self-renewal, and apoptosis. Since ALDHs are involved in some of these biological processes, the deregulation of these enzymes may influence MDS and AML development. The aim of the study is to evaluate the gene expression of ALDHs in patients with MDS and AML in order to verify their potential as a biomarker for the diagnosis and/or prognosis of these diseases. To this end, we did a preliminary analysis of the expression levels of ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, ALDH1L2, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH7A1, ALDH16A1, and ALDH18A1. Then, we analyzed gene expression of ALDH3A2, ALDH3B1, ALDH4A1, and ALDH18A1 in 54 patients, 34 MDS and 20 AML, and 34 healthy controls. ALDH expression levels were analyzed using Reverse Transcriptase-PCR and differentially expressed genes were quantified by qPCR. The statistical analysis was carried out by the Kolmogorov-Smirnov Test, Mann-Whitney test, Kruskal-Wallis test, and ROC analysis. A value of p < 0.05 was considered significant. The results indicate that ALDH1A3, ALDH1L1, ALDH1L2, ALDH3A1, ALDH3B2, and ALDH5A1 did not show differences in their expression between MDS, AML, and controls. ALDH3A2, ALDH3B1, ALDH4A1, and ALDH18A1 had differential expression among study groups and were quantified by real time PCR. MDS and AML patients showed higher expression of ALDH3A2 (MDS: median 1.9251; interquartile range 1.28; p=0.000618; AML: median 1.5096; interquartile range 0.99; p=0.008) and ALDH4A1 (MDS: median 0.1841; interquartile range 0.47; p=0.01134; AML: median 0.1635; interquartile range 0.78; p=0.124) in comparison with controls (ALDH3A2: median 0.4624; interquartile range 1.53; ALDH4A1: median 0.0388; interquartile range 0.12). On the other hand, the expression of ALDH3B1 was higher in MDS patients (median 1.6445; interquartile range 1.39) than in AML patients (median 0.4541; interquartile range 0.47; p=0.000314) and controls (median 0.3521; interquartile range 0.51; p=5.9942E-07). ALDH3A2 and ALDH3B1 also showed statistically significant differences between the different subtypes of MDS. Additionally, patients with MDS and AML with myelodysplasia related changes (AML-MRC) did not expressed ALDH18A1. When we compared MDS patients according to WHO classification-based prognostic scoring system (WPSS) risk groups it was found that patients with very low risk had higher expression of ALDH3B1 (median 17.6934; interquartile range 16.32) in comparison with patients with intermediate risk (median 1.2352; interquartile range 2.55; p=0.010). Furthermore, the expression of ALDH isoforms does not appear to influence MDS and AML patient’s overall survival or MDS evolution to AML. In summary, ALDH isoforms have differential expression patterns in MDS and AML patients when compared with controls and each other. The ALDH3B1 is a potential diagnostic biomarker of MDS. Since none MDS and AML-MRC patients expressed ALDH18A1, the expression of this isoform may be a good diagnostic biomarker. Finally, ALDH3A2 could be a diagnostic biomarker of AML. However, further studies with a higher number of participants are needed to prove the potential of these enzymes as diagnostic biomarkers.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Potential biomaker"

1

Lee, Amanda Jayne. Potential biomarkers of cancer risk associated with exposure to hexavalent chromium. Birmingham: University of Birmingham, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ballachey, Brenda Elizabeth. Biomarkers of damage to sea otters in Prince William Sound, Alaska, following potential exposure to oil spilled from the Exxon Valdez. Anchorage, AK: U.S. Fish and Wildlife Service, Alaska Fish and Wildlife Research Center, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ballachey, Brenda Elizabeth. Biomarkers of damage to sea otters in Prince William Sound, Alaska, following potential exposure to oil spilled from the Exxon Valdez. Anchorage, AK: U.S. Fish and Wildlife Service, Alaska Fish and Wildlife Research Center, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ballachey, Brenda Elizabeth. Biomarkers of damage to sea otters in Prince William Sound, Alaska, following potential exposure to oil spilled from the Exxon Valdez. Anchorage, AK: U.S. Fish and Wildlife Service, Alaska Fish and Wildlife Research Center, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blumenberg, Miroslav, ed. Human Skin Cancer, Potential Biomarkers and Therapeutic Targets. InTech, 2016. http://dx.doi.org/10.5772/61922.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tenovuo, Olli, Jean-charles Sanchez, Damir Janigro, and Johan Undén, eds. Biomarkers of Brain Damage – A Complex Challenge with Great Potential. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-754-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Biomarkers and cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0040.

Full text
Abstract:
Biomarkers and cancer defines these markers and outlines their role in diagnosis, prognosis, prediction of response, and response assessment of a variety of cancers. Established biomarkers are reviewed, and the potential for development of new biomarkers offered by the dramatic progress in both the understanding of molecular biology and the development of laboratory techniques is emphasised. The field of signal transduction has already proved fruitful, with identification of markers allowing successful targeted therapy in a range of cancers. Progress is anticipated also in tumour imaging, with developments in both MRI and PET. Areas of clinical interest are summarised for breast, lung, colorectal, renal, and CNS malignancies.
APA, Harvard, Vancouver, ISO, and other styles
8

Nizari, Shereen, Cheryl Hawkes, Anusha Mishra, and Yorito Hattori, eds. The Neurovascular Unit as a Potential Biomarker and Therapeutic Target in Cerebrovascular Disease. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-238-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Prowle, John R. Renal injury biomarkers in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0302.

Full text
Abstract:
Acute kidney injury (AKI) is a common complication of critical illness and its occurrence has been independently associated with both short- and longer-term morbidity and mortality. However, conventional diagnosis of AKI, based on rises in serum creatinine, can be delayed and inaccurate, particularly in the context of critical illness. These diagnostic limitations potentially prevent timely intervention and appropriate follow-up of patients experiencing AKI. Recently, a number of novel urinary and serum biomarkers of AKI have been described that may provide earlier and more precise diagnosis. Importantly, a number of these substances are biologically-linked to the pathophysiology of acute tubular injury. However, true validation and widespread clinical uptake of these biomarkers is likely to require demonstration of improved patients’ outcomes as a consequence of biomarker-driven clinical interventions.
APA, Harvard, Vancouver, ISO, and other styles
10

Farooqui, Akhlaq A. Neurochemical Aspects of Alzheimer's Disease: Risk Factors, Pathogenesis, Biomarkers, and Potential Treatment Strategies. Elsevier Science & Technology Books, 2017.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Potential biomaker"

1

Sloan, Philip. "The Bi-Directional Communication Between Tumour Cells and Other Components of the Tumour Microenvironment." In Critical Issues in Head and Neck Oncology, 1–9. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23175-9_1.

Full text
Abstract:
AbstractCross talk between cancer cells and their microenvironment can lead to molecular changes in adjacent tissues that can be utilised as biomarkers. One such example stems from the discovery that malignant melanomas with metastatic potential can downregulate autophagy in the overlying epidermis. Autophagy is essential for normal keratinocyte maturation. AMBRA1 is a key autophagy regulatory molecule and its expression in the epidermis is reduced in the epidermis overlying some early stage melanomas. Expression of AMBRA1 is maintained in the overlying epidermis in a subset of low risk melanomas. This finding has been translated into a novel biomarker for clinical use. Preliminary data suggest that AMBRA1 expression in neoplastic cells may be a useful biomarker for prediction of risk of progression in oropharyngeal and cutaneous squamous cell carcinoma. It is likely that it will be necessary to combination biomarker expression with Artificial Intelligence analysis and convention staging to provide accurate individualised prognostic information for clinical use.
APA, Harvard, Vancouver, ISO, and other styles
2

Notter, Tina. "Immunological Processes in Schizophrenia Pathology: Potential Biomarkers?" In Biomarkers in Psychiatry, 389–410. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/7854_2018_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Miyake, Hideaki, Atsushi Takenaka, and Masato Fujisawa. "Biomarkers of Potential Therapeutic Value." In Prostate Cancer: A Comprehensive Perspective, 181–87. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2864-9_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lotsberg, Maria Lie, and Stacey Ann D’mello Peters. "Publication Bias in Precision Oncology and Cancer Biomarker Research; Challenges and Possible Implications." In Human Perspectives in Health Sciences and Technology, 155–74. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92612-0_10.

Full text
Abstract:
AbstractPublication bias and lack of information sharing are major obstacles in scientific research. Indeed, a lot of time, money and effort might be misspent on research that has already been undertaken, but not published. Over time, this causes a bias in the scientific literature that has implications for researchers designing new research projects or interpreting results. It also affects society and decision-making processes as important scientific knowledge is not shared, used, and critically discussed. In the specific context of medical research, publication bias can have a great impact on patients’ lives, as they could potentially have received a more adequate treatment or avoided harmful side-effects. The issue of publication bias seems even more stringent for precision oncology and biomarker research, as aiming for perfection or ‘hyper precision’ will leave even less space for ‘negative’ results than in medical research in general. Indeed, although a lot of resources are spent on cancer biomarker research, still only a few biomarkers end up in the clinic, and even for those that “succeed” in this process, there are still challenges with defining cut-offs for biomarker positive and negative subgroups as well as deciding how to treat the biomarker defined subgroups in a most optimal way. The aim of this chapter is to explore the extent of publication bias in the context of precision oncology and cancer biomarker research: its implications on researchers, patients, and society, as well as to reflect on the deeper roots of the problem.
APA, Harvard, Vancouver, ISO, and other styles
5

Anjum, Naser A., Sarvajeet Singh Gill, Armando C. Duarte, and Eduarda Pereira. "Oxidative Stress Biomarkers and Antioxidant Defense in Plants Exposed to Metallic Nanoparticles." In Nanomaterials and Plant Potential, 427–39. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-05569-1_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Philips, Thomas, and Rita Sattler. "Glial Glutamate and Metabolic Transporters as a Target for Neurodegenerative Therapy and Biomarkers." In Pathological Potential of Neuroglia, 61–88. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0974-2_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Simões e Silva, Ana Cristina, André Barreto Pereira, Mauro Martins Teixeira, and Antônio Lúcio Teixeira. "Chemokines as Potential Markers in Pediatric Renal Diseases." In Biomarkers in Kidney Disease, 229–48. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7699-9_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Simões e Silva, Ana Cristina, André Barreto Pereira, Mauro Martins Teixeira, and Antônio Lúcio Teixeira. "Chemokines as Potential Markers in Pediatric Renal Diseases." In Biomarkers in Kidney Disease, 1–20. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7743-9_39-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Perkovic, Matea Nikolac, Gordana Nedic Erjavec, Dubravka Svob Strac, and Nela Pivac. "Biomarkers of Depression: Potential Diagnostic Tools." In Understanding Depression, 35–51. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-6577-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Iuliano, Luigi, and Ulf Diczfalusy. "Oxysterols: Potential Biomarkers of Oxidative Stress." In Biomarkers for Antioxidant Defense and Oxidative Damage: Principles and Practical Applications, 99–115. Oxford, UK: Wiley-Blackwell, 2010. http://dx.doi.org/10.1002/9780813814438.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Potential biomaker"

1

Juratli, M., S. Sliwinski, E. Oppermann, A. Lorentzen, A. Pascher, WO Bechstein, and M. Heikenwälder. "Ezrin-polarized circulating tumor cells as a potential biomaker in hepatocellular carcinoma." In 37. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0040-1721999.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Brum, Wagner, Andrei Bieger, Joao Pedro Ferrari Souza, Marco de Bastiani, Andrea Benedet, Nicholas Ashton, Tharick Pascoal, et al. "A THREE-RANGE APPROACH ENHANCES PROGNOSTIC UTILITY OF CSF BIOMARKERS IN ALZHEIMER’S DISEASE." In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda022.

Full text
Abstract:
Background: Alzheimer’s disease (AD) was biologically defined by the 2018 NIA-AA Research Framework (RF), which recommends dichotomously defining biomarker status as normal or abnormal with single cutpoints. However, a three-range approach remains unexplored in AD fluid biomarkers. Objective: To assess the prognostic utility of a three-range approach for CSF biomarkers in AD. Methods: We included 1278 non-demented individuals (CU: n=575; MCI: n=703) from the ADNI with baseline CSF Elecsys® biomarkers. Within it, we defined three-range cutpoints with two-graph receiver operating characteristics (TGROC) for each CSF biomarker (Aβ1-42, p-tau, p-tau/Aβ1-42), based on amyloid PET positivity. Then, linear mixed-effects and Cox proportional hazards models were used to estimate longitudinal cognitive trajectories and risk of clinical progression based on CSF biomarker status. Hereby derived three-range cutpoints were compared to previously described binary thresholds for the same biomarkers. Power analyses for simulated trials were also carried. Results: We observed dynamic amyloid-PET changes for participants in the intermediate range, while a static profile for clearly normal and abnormal groups. Longitudinally, our approach revealed a divergent intermediate cognitive trajectory undetected by dichotomization, with power analyses demonstrating potential applications for trial enrichment. Conclusion: The proposed approach can improve CSF-based diagnosis, refine prognostic assessment and enhance clinical trial recruitment.
APA, Harvard, Vancouver, ISO, and other styles
3

Kallingal, Nithusha, Kishor Kumar Sadasivuni, Issam Bahadur, Huseyin Cagatay Yalcin, Asiya Al-Busaidi, Hassen M. Ouakad, and Somaya Al-Maadeed. "Colorimetry-based Detection of Exhaled Breath Biomarkers for Predicting Heart Failure." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0077.

Full text
Abstract:
The exhaled breath volatile organic compounds (VOC’s) represent a biosignature with the potential to identify and describe heart failure diseases. Exhaled Breath biomarkers-based diagnosis of heart diseases may be easier and earlier detection than other available techniques. So, this is a review of combining both exhaled breath analysis with cost effective colorimetry technology to detect biomarkers for heart failure diseases. We also studied the effectiveness of biomarker trimethyl amine for cardiovascular diseases detection.
APA, Harvard, Vancouver, ISO, and other styles
4

Shah, Samar, Yaling Liu, and Walter Hu. "Characterization of Biosensor Detection Process at Ultra-Low Concentration Through a Stochastic Particle Model." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13069.

Full text
Abstract:
Biosensor detection process involves binding between biomolecules in a solution and a functionalized sensor surface. These sensors are time and cost efficient, sensitive, and enable new applications in medicine, drug design, and environmental monitoring. In literatures, various biosensor designs have been proposed, such as planar electrodes, nanowire, and nanospheres for different applications. However, to fully realize the potentials of these biosensors for biomarker/nanoparticle detection, several challenges must be addressed. In particular, ultra-sensitive biosensors are needed for detection of ultra-low concentration biomarkers such as cancer markers for early disease detection. The goal of this paper is to understand the diffusion process of biomarkers in a liquid solution and the binding with nanosensor surface through a stochastic particle model.
APA, Harvard, Vancouver, ISO, and other styles
5

Azevedo, Fernanda Reis de, Michael Polydefkis, Simina Ticau, David Erbe, Anastasia McManus, Emre Aldinc, David Adams, Mary Reilly, Akshay Vaishnaw, and Paul Nio. "Neurofilament Light Chain (NfL) as a Potential Biomarker of Treatment Response in Hereditary TransthyretinMediated (hATTR) Amyloidosis: Patisiran Global OLE Study." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.200.

Full text
Abstract:
Introduction: Patisiran is approved for the treatment of hATTR amyloidosis with polyneuropathy and its long-term efficacy/safety is being studied in a Global OLE. Plasma biomarkers are being investigated for utility in facilitating earlier diagnosis and monitoring disease /treatment response. Objective: Evaluate long-term change in neurofilament light chain (NfL) levels in response to patisiran in patients enrolled in the Global Open-Label Extension (OLE) study. Methods: NfL plasma levels were measured in duplicate in healthy controls and patients with ATTRv amyloidosis with polyneuropathy using the Quanterix Simoa platform. Patient samples were analyzed from the APOLLO study at baseline and 18 months, and also measured at 12 and 24 months following APOLLO in patients who rolled into the Global OLE. Results: NfL levels at APOLLO baseline were 63.2 (placebo) and 72.1 pg/ mL (patisiran). NfL increased during APOLLO in the placebo group (99.5 pg/mL), whereas a significant decrease was observed at 18 months following patisiran (48.8 pg/mL). Reduced NfL levels were maintained in the APOLLO-patisiran group through 24 months of additional patisiran treatment in the Global OLE (44.0 pg/mL), consistent with maintained improvement in mNIS+7. Upon initiation of patisiran in the Global OLE, the APOLLO-placebo group experienced a reduction in NfL levels through 24 months (44.2 pg/mL), reaching a similar level to the APOLLO-patisiran group. Conclusions: NfL may serve as a biomarker of active nerve damage and polyneuropathy, making it useful as a potential biomarker of disease progression, treatment response and for earlier diagnosis of polyneuropathy in patients with ATTRv amyloidosis and monitoring disease.
APA, Harvard, Vancouver, ISO, and other styles
6

Seitkhaziyev, Yessimkhan Sherekhanovich, Nariman Danebekovich Sarsenbekov, and Rakhim Nagangaliyevich Uteyev. "Geochemical Atlas of Oils and Source Rocks and Oil-Source Rock Correlations: A Case Study of Oil and Ggas Fields in the Mangyshlak Basin (Kazakhstan)." In SPE Annual Caspian Technical Conference. SPE, 2022. http://dx.doi.org/10.2118/212078-ms.

Full text
Abstract:
Abstract This paper presents the results of fingerprinting and biomarker analysis of 183 crude oil samples derived from 19 oil and gas fields in the South Mangyshlak basin and Rock -Eval pyrolysis performed on 93 core samples from 12 fields of this basin. Geochemical atlas was made based on the oil fingerprinting studies, according to which, the studied fields of the South- Mangyshlak basin can be divided into 3 groups: same type of oils on the scale of groups of fields. This group includes Permian-Triassic oils of the Karaginskaya Saddle (Northern Karagiye, Atambay, Alatyube, Ashchiagar) and the Peschannomyssko-Rakushechnaya uplift zone (Oymasha), which have very similar oil fingerprinting either within each field or on the scale of these fields. oils of the same type within the same field. The second group includes oils from Pridorozhnoye, Airantakyr, Burmasha and Bekturly fields, each of which has its own unique oil fingerprinting of light aromatic hydrocarbons. different types of oils within the same field. This group includes oils from the rest of the studied Zhetybay- Uzen steps such as Asar, East Zhetybay, South Zhetybay, Aktas, Turkmenoy, Tasbulat, Uzen and Karamandybas fields, since within each of these fields were identified several different groups of oils that require a detailed study of their biomarkers to determine their genetic origin and trace hydrocarbon migration pathways. The obtained results of oil fingerprinting are consistent with their biomarker compositions, according to which the oils of the first group, identified by their fingerprinting, were generated from marine shaly source rocks, while those of the second group were from shaly source rocks, deposited in whether marine or lacustrine environments. The biomarker composition of the third group oils exhibited that the oils within each of these fields have at least two genetic sources: the oils of the lower pay zones have shaly marine OM source, while those of the upper upper pay zones were formed by OM deposited in lacustrine environment. Their biomarkers clearly show a regular change in the contribution of lacustrine OM input to marine one with the depth increase of pay zones and within the field of this group thermally more mature oils of a marine source (23-24 horizons Uzen and Karamandybas, J-10 and J-11 fields of Asar, Zhetybay, Zhetybay East) were mixed with relatively lower mature oils of the upper lacustrine source (13-16 th pay zones in Uzen and Karamandybas, J-J-3a, J-4a in Asar field, J-5 in Zhetybay, J-1 in Zhetybay East) with their upward migration. To characterize source rocks, where the studied oils were generated, Rock-Eval pyrolysis was performed on core samples of different ages, which revealed that in reality the reservoirs of the Asar, Zhetybay, Karamandybas, Uzen and Akkar fields can be considered synclinal, that means, it serves as both reservoir and source rock, which explains the different oil fingerprintings and the vertical and lateral differences in their biomarkers. The main role in the formation of deposits in the stratum played the lateral migration of hydrocarbons from the most submerged parts. Rock -Eval results also enabled to clarify the reasons for the different compositions of oil biomarkers: for example, by pyrolysis, the studied core samples from the Permian- Triassic and Triassic deposits of Oymashaa, Atambay -Sartyube and Pridorozhnoye are so thermally overmature that they are in the zone of gas generation and possess low generative potential, and as shown by biomarker analysis, their oils have such a high thermal maturity that only tiny amount of biomarkers is left. This circumstance is reflected in a sharp reduction in the resources of liquid hydrocarbons in Permian- Triassic deposits compared to Jurassic deposits and in an equally sharp increase in the share of gas formation. Also "oil-source rock correlation" studies were made to discern genetic link between oils and hydrocarbons extracted from potential source rocks.
APA, Harvard, Vancouver, ISO, and other styles
7

OLIVEIRA, SANDRA MAXIMIANO DE, IGHOR LUIZ AZEVEDO TEIXEIRA, CAROLINA NUNES FRANÇA, CRISTIANE KAYSER, LUCAS GARCIA BIAGI, and MARIA CRISTINA DE OLIVEIRA IZAR. "MICROPARTICLES IN SYSTEMIC SCLEROSIS: POTENTIAL NEW BIOMARKER?" In 36º Congresso Brasileiro de Reumatologia. São Paulo: Editora Blucher, 2019. http://dx.doi.org/10.5151/sbr2019-514.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Celik, Emrah, Nicolas Rongione, Amelia Bahamonde, Zheng Ao, and Ram Datar. "Isolation of Circulating Tumor Cells Using Stiffness-Based Filtration Platform." In ASME 2015 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2015. http://dx.doi.org/10.1115/imece2015-53241.

Full text
Abstract:
Analysis of isolated cancer cells in circulation is proven to help determine the success of the cancer treatment and understand the genetic signature of cancer disease. Scarcity of these cells in blood circulation (1–10 CTC in 1ml blood) however, makes the isolation process extremely challenging. Ever improving CTC isolation methods fall into two main categories: 1.Immunomagnetic separation based on antibody binding to tumor specific biomarkers expressed on the cell 2. Physical separation based on the size of the CTCs. Efficiency in cell isolation is still low in these techniques due to the variation in expression level of tumor specific antigens and tumor cell size. Therefore, tumor cell isolation strategies using new CTC biomarkers must be explored. In this study, we investigated the feasibility of using mechanical stiffness difference in order to detect and isolate the circulating tumor cells from the blood cells. AFM nanindentation experiments revealed that cancer cells are significantly softer than the surrounding white blood cells and therefore, stiffness can be used as a biomarker for CTC isolation. In addition, finite element analysis simulations have shown that CTC isolation can be performed at high efficiency using stiffness-based isolation. Therefore, stiffness based isolation has a potential to achieve fast, label-free isolation of CTCs at high efficiency for clinical applications.
APA, Harvard, Vancouver, ISO, and other styles
9

Tanino, Y., X. Wang, Y. Inokoshi, K. Saito, N. Nakagawa, S. Sato, T. Ishii, et al. "Syndecan-4 as a Potential Biomarker for Sarcoidosis." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nguyen, Thanh-Qua, Jeongyun Kim, Daewoong Lee, Ji-Seob Choi, Jaeho Park, Hojeong Jeon, Woo-Tae Park, and Sangyoup Lee. "Immobilization of Magnetic Beads for Microfluidic Immunoassays." In ASME-JSME-KSME 2019 8th Joint Fluids Engineering Conference. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/ajkfluids2019-5401.

Full text
Abstract:
Abstract Employing magnetic beads (MBs) to microfluidic chips has enabled diverse microscale biomedical applications involving isolation of target molecules, such as, separation, and biosensing. In this report a microfluidic immunoassay chip that can temporarily immobilize MBs for the detection of target biomarkers within a sample solution flown through its channels is introduced. A through-hole structure of the MB capture zone and valves that can control the direction of the flow enabled immobilization of MBs with high reproducibility. Controlling immobilization of MBs shows promise for reproducible immunoassay signal detections for the same concentration of biomarker which is crucial for quantification of the assay. In addition, the structure and position of the captured MBs can potentially be optimal for immunoassay performances where immunoassay reagents including the antigen and the detection antibody are flown through the MB captured through hole maximizing contact for high binding efficiencies.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Potential biomaker"

1

Petkova, Boryana, Emilia Alova, Iliya Karagyozov, Polya Stoyanova, Vladimir Jekov, Milena Mourdjeva, and Tsvetelina Oreshkova. IL-10: a Potential Prognostic Biomarker for Missed Abortion. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, July 2019. http://dx.doi.org/10.7546/crabs.2019.07.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

MARTÍNEZ LEAL, LAURA DE LA CRUZ, and Carlos Romá Mateo. Preliminary proteomics analysis of the potential use of HMGB1 as sepsis biomarker. Fundación Avanza, May 2023. http://dx.doi.org/10.60096/fundacionavanza/2312022.

Full text
Abstract:
With this study, we evaluate the first steps into the development of a new possible biomarker for sepsis disease consisting in detection of HGMB1 protein in plasma, using mass spectrometry (MRM-MS), that could improve sepsis clinical management.
APA, Harvard, Vancouver, ISO, and other styles
3

Ma, Yunxing, Julia Brettschneider, and Joanna Collingwood. A systematic review and meta-analysis of cerebrospinal fluid amyloid and tau levels in patients progressing from Mild Cognitive Impairment to Alzheimer’s Disease. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0020.

Full text
Abstract:
Review question / Objective: Reported levels of amyloid-beta and tau in human cerebrospinal fluid (CSF) are evaluated to discover if these biochemical markers can predict the transition from Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD). A systematic review and quantitative meta-analyses are performed to test relationships between three potential biomarkers in CSF (Aβ(1-42), T-tau, and P-tau181) and the evolution of AD in longitudinal evaluations of levels relative to baseline, using prior-published experimental data. The primary focus of the analysis is on the period describing the transition of a patient from MCI to AD, where it is critical to discover the main biomarker characteristics that differentiate patient outcomes for those who have a stable form of MCI, and those who progress to a confirmed diagnosis of AD. A secondary purpose of the review was to examine the status of iron in CSF as a function of disease status.
APA, Harvard, Vancouver, ISO, and other styles
4

Swaby, Ramona. Cancer-Associated PCNA as a Potential Biomarker for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2010. http://dx.doi.org/10.21236/ada549224.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Podlevsky, Joshua. Cas9 Protein Post-translational Modifications (PTMs): A Potential Biomarker of Gene-editing. Office of Scientific and Technical Information (OSTI), October 2019. http://dx.doi.org/10.2172/1571552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Carlson, Kelsey, Kenneth J. Prusa, Chris A. Fedler, Ed M. Steadham, Elisabeth J. Huff-Lonergan, and Steven M. Lonergan. Desmin and Peroxiredoxin-2 are Potential Biomarkers for Pork Tenderness. Ames (Iowa): Iowa State University, January 2017. http://dx.doi.org/10.31274/ans_air-180814-313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cupples, Alison M. Development of Biomarkers for Assessing In Situ RDX Biodegradation Potential. Fort Belvoir, VA: Defense Technical Information Center, February 2010. http://dx.doi.org/10.21236/ada573427.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Karow, David S. MRI-Derived Cellularity Index as a Potential Noninvasive Imaging Biomarker of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada616253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sun, Peiquing. Identification of Potential Biomarkers for the Early Diagnosis of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2003. http://dx.doi.org/10.21236/ada421783.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

bao, qiangji, Xin ting Wu, Shu-Jun Chen, Jin-Tao Zhang, Kai Zhao Zhang, Yu Guo, Xiao-Feng Du, and Ming-Fei Yang. Potential Biomarkers for Post-Stroke Depression: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Potential biomaker' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography